ALLSCHWIL, Switzerland, July 20, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX) a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company will hold a business update call on Thursday, July 28, 2022, at 8 AM EDT / 2 PM CET.
To participate, please use the following numbers:
| France: | +33 (0)1 70 730 3 39 | |
| Germany: | +49 (0)69 22222 5197 | |
| Italy: | +39 0200638217 | |
| Switzerland: | +41 (0)44 580 7279 | |
| United Kingdom: | +44 (0)330 165 4012 | |
| United States: | +1 646-828-8075 |
Please dial in approximately 10 minutes prior to the start of the call. When asked, please provide the name of the event – “Spexis AG - Business and Strategy Update” – and the following confirmation code: 1507661.
The presentation will also be available via webcast:
- For participants of the conference call: https://www.webcast-eqs.com/spexis20220728/ no-audio (audio via phone, presentation on the web browser)
- Live stream: https://www.webcast-eqs.com/spexis20220728 (audio and presentation on the web browser; for passive participants)
A replay of the call will be available on the Company’s website in the Investor Relations – Calendar section here or via the above link.
For further information, please contact:
| For Investors: Hernan Levett Chief Financial Officer Spexis AG. +41 61 567 16 00 IR@spexisbio.com Raimund Gabriel MC Services spexis@mc-services.eu Ph: +49 89 210 228 0 | For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 92 56 feldhaus@feldhaus-partner.ch Dr. Brigitte Keller/Laurie Doyle MC Services spexis@mc-services.eu Europe: +49 89 210 228 0 U.S.: +1 339 832 0752 |
About Spexis
Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on rare diseases and oncology. For further information, please visit: www.spexisbio.com.
Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis' results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only as of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
